SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotify is rallying after its Q3 report, with traders focusing on premium subscriber growth, improving gross margin and a stronger Q4 profit outlook despite a revenue and EPS miss. Bulls see the forward guidance as the key signal, while bears question the spending and the sharp move higher despite the missed estimates.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASMLs quarterly results and outlook are driving attention: management described strong AI-related demand that could exceed planned equipment supply, while raising its sales outlook. The shares have nevertheless sold off, prompting debate over a sell the news reaction and whether elevated expectations, valuation concerns, or broader weakness in semiconductor stocks outweighed the upbeat demand signal.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons better-than-expected third-quarter results, particularly strong refining performance and record refinery throughput, are the main focus. Traders are celebrating the earnings beat and new highs, while some question whether elevated refining margins can last and whether the rally is overextended.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The Other segment includes DLP products, calculators, and custom application-specific integrated circuits products. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments strong Q3 results and above-consensus Q4 outlook are driving discussion, alongside the stocks recent rally and breakout. Traders are split between viewing the results and call buying as bullish and treating put activity and the pullback as hedging or profit-taking.

Generac Holdings, Inc. engages in the business of designing and manufacturing energy technology solutions. It operates under the Domestic and International segments. The Domestic segment includes the legacy Generac business and the acquisitions that are based in the United States and Canada. The International segment focuses on Generac business' Latin American export operations. The company was founded in 1959 and is headquartered in Waukesha, WI.

Generac Holdings Inc

Generacs quarterly results and its growing data-center business are the main focus, with traders highlighting the Amazon supply agreement and expanding backlog as support for its AI infrastructure story. Views are mixed: some see strong commercial growth and an earnings beat, while others point to a sales shortfall, unchanged full-year guidance, thinner commercial margins and profit-taking.

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99995246 in circulation. The last known price of Compound is 20.49527411 USD and is down -2.02 over the last 24 hours. It is currently trading on 652 active market(s) with $25,001,434.49 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Traders are focused on Compounds institutional-market rollout and reported treasury-backed expansion, which bulls see as a potential boost to its DeFi business. Others remain skeptical, pointing to COMPs weak performance versus other crypto assets and its difficulty sustaining gains.

Pyth Network (PYTH) is a cryptocurrency launched in 2021and operates on the Solana platform. Pyth Network has a current supply of 9,999,981,857.422035 with 7,874,958,864.894765 in circulation. The last known price of Pyth Network is 0.06503621 USD and is up 3.48 over the last 24 hours. It is currently trading on 450 active market(s) with $50,940,939.77 traded over the last 24 hours. More information can be found at https://pyth.network/.

Pyth Network

Discussion centers on Pyths revenue-linked buyback policy and Nasdaq data distribution, which traders cite as evidence of growing utility and RWA adoption. Optimism about a recovery and a teased quarterly announcement is tempered by concerns about token supply, volatility, and whether revenue-driven demand will be enough.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of Voceryq, a competing treatment for recurrent respiratory papillomatosis, has raised concerns about competition for Precigens PAPZIMEOS. Traders debate whether the rival will erode PAPZIMEOS sales, citing its potential to reduce surgeries while also pointing to Precigens first-mover advantage, full-approval status, and Inovios commercialization and funding challenges.

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,387.69. The last known price of BNB is 703.59425696 USD and is up 0.47 over the last 24 hours. It is currently trading on 3523 active market(s) with $2,735,089,335.64 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

Discussion is dominated by reports of a major Binance security breach and stolen crypto, prompting concerns about customer fund safety, suspended withdrawals, and possible spillover across crypto markets. Traders debate whether Binance can cover losses and whether the incident signals deeper exchange risks, while some point to frozen assets and the tokens relative resilience.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is drawing attention as crude oil trades on U.S.-Iran tensions and risks to Strait of Hormuz shipping, with traders debating whether supply disruptions will sustain prices or a diplomatic deal will unwind the risk premium. Bulls emphasize constrained supply and fuel shortages, while bears point to possible de-escalation, oversupply and inventory builds, and volatility decay in the leveraged fund.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

This Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

Analysts downgraded Qiagen, Alcoa and Dutch Bros, cutting price targets for Qiagen to $52 and Dutch Bros to $46.read more...

QGEN Stock Alert: Halper Sadeh LLC is Investigating Whether QIAGEN N.V. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of QIAGEN N.V. (NYSE: QGEN) to the EQT XI fund for 46.50 in cash per share.Halper Sadeh encourages QIAGEN shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free...

QIAGEN reports preliminary Q3 2026 results

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary third-quarter 2026 financial results. Net sales were $548 million at both reported and constant exchange rates (CER). Adjusted diluted earnings per share (EPS) were $0.65, also $0.65 CER. QIAGEN plans to report full...

QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (QIAGEN or the Company) and the EQT XI fund (EQT Private Equity) today announced an agreement under which Crown NL Bidco B.V. (the Bidder) announced its decision to make an all-cash voluntary public takeover offer for the acquisition of all...

QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) will bring together tuberculosis experts from around the world for the Global TB Clinical and Educational Summit from October 13-16 as a persistent disease burden and growing pressures on global health funding put renewed focus on tuberculosis...

QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new artificial intelligence (AI) capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible. The expansion includes IPA Investigator, a...

QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel

QGEN expands its U.S. QIAstat-Dx portfolio with an FDA-cleared panel that detects gram-negative bacteria and resistance markers in about one hour.

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Food and Drug Administration (FDA). The new panel detects gram-negative bacteria...

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

Qiagen NV

QGEN Stock Clocks Biggest Single-Day Gains In Nearly Six Months – Investor Optimism Jumps On Report About Takeover Interest 

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Some potential bidders are considering an offer of at least $50 per share, the report stated.</li><li>QGEN has a 12-month consensus price target of $44.46, according to data from 15 analysts.</li><li>The company has been exploring strategic options, with CEO Thierry Bernard stating the company was working with Moelis &amp; Co. and Goldman Sachs.</li></ul>Shares of Qiagen (QGEN) surged more than 10% on Thursday to hit their highest intraday level in four months after a report said several private equity firms were exploring a potential takeover of the molecular diagnostics company.<a href="https://stocktwits.com/symbol/QGEN">QGEN shares</a> also recorded their biggest single-day gains in almost six months.<h2 class="st-heading-2">Reported Takeover Offers Imply At least 16% Premium</h2>According to a Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-07-09/qiagen-draws-early-takeover-interest-from-eqt-advent">report</a> on Thursday, EQT, Advent, and KKR &amp; Co. (KKR) are among the firms that have expressed interest in acquiring Qiagen. Some potential bidders are considering an offer of at least $50 per share, the report stated, citing sources familiar with the matter. This represents a roughly 16% premium to current levels and a near 28% premium to the stock’s closing price on Wednesday.The renewed takeover interest follows reports earlier this year that Qiagen had begun reviewing strategic options. In March, CEO Thierry Bernard said the company was working with Moelis &amp; Co. and Goldman Sachs on the review. The company has attracted acquisition interest several times in recent years, though previous talks did not result in a deal, the report stated.<h2 class="st-heading-2">Bid Could Exceed Wall Street’s Price Target On QGEN</h2>The potential bid exceeds Wall Street’s price target for the stock. Based on data from 15 analysts, QGEN has a 12-month consensus price target of $44.46. Wall Street remains broadly bullish on the stock, with nine analysts rating it a “Buy” and the remaining six recommending “Hold,” according to Koyfin.Morgan Stanley recently upgraded Qiagen to ‘Overweight’ from ‘Equal Weight’ and raised its price target to $42 from $40. The firm believes the stock’s valuation offers an attractive risk-reward profile, describing Qiagen as a “structural winner” from the post-pandemic demand for molecular testing.Qiagen develops molecular testing technologies used by pharmaceutical companies, research institutions, and clinical laboratories for genetic analysis and disease detection.Recently, Qiagen introduced research-use-only digital PCR assays to support surveillance and research related to the Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo and Uganda. The assays target key parts of the virus, called nucleoprotein and VP35, to help researchers monitor emerging pathogens.<h2 class="st-heading-2">Retail Turns Bullish On QGEN</h2>Retail sentiment surrounding QGEN on Stocktwits turned ‘bullish’ from ‘neutral,’ amid ‘high’ message volumes.One user said a “decent” takeover target would be $60 per share.&nbsp;<stembedurl>https://stocktwits.com/Riteman/message/658652526</stembedurl>The stock has declined around 5.5% so far this year.Also read:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-tops-900-billion-market-capitalization-again-can-it-follow-micron-to-1-trillion-valuation/cZmYRFjR7nK">AMD Tops $900 Billion Market Capitalization Again — Can It Follow Micron To $1 Trillion Valuation?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the QIAGEN logo is seen displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Shares of Qiagen (QGEN) surged more than 10% on Thursday to hit their highest intraday level in four months after a report said several private equity firms were exploring a potential takeover of the molecular diagnostics company.

According to a Bloomberg report on Thursday, EQT, Advent, and KKR & Co. are among the firms that have expressed interest in acquiring Qiagen.

KKR & Co. Inc.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$50.22
Prev Close	$50.34
Open	$50.35
Dividend Yield	0.56%
50-Day Moving Average	$45.11
Beta	0.57
Avg. Volume	1.94M
PE Ratio	25.51

52-Week High	$57.82
52-Week Low	$32.53
Market Capitalization	$10.37B
EPS (Annual)	$2.04
Price to Book	3.09
Revenue Per Employee	$369,649.63

Feed

News

Sentiment

Earnings

Fundamentals

Info

QGEN Fundamentals